https://scholars.lib.ntu.edu.tw/handle/123456789/537521
標題: | Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma | 作者: | Li C.-C. HWEI-FANG TIEN JIH-LUH TANG MING YAO YAO-CHANG CHEN Su I.-J. Hsu S.-M. RUEY-LONG HONG |
公開日期: | 2004 | 卷: | 100 | 期: | 2 | 起(迄)頁: | 366-375 | 來源出版物: | Cancer | 摘要: | BACKGROUND. Sinonasal natural killer (NK)/T-cell or T-cell lymphoma behaves quite differently from other lymphomas. The objective of this study was to investigate clinical features, treatment outcomes, and failure patterns in patients with this type of sinonasal lymphoma. METHODS. From September, 1977 to December, 2000, 77 patients with sinonasal NK/T-cell lymphoma or T-cell lymphoma who had received radiotherapy (R/T), chemotherapy (C/T), or both (R/T and C/T) were evaluated retrospectively. RESULTS. Fifty-six patients (73%) had locoregional disease only, and 21 patients (27%) had systemic involvement. Forty-four patients (57%) achieved a complete remission (CR). The 5-year overall survival rate was 36% (median follow-up, 89 months). Achievement of CR was the only prognostic factor for survival in multivariate analysis. Among patients with locoregional disease, the CR rate was 63%, and the 5-year overall survival rate was 42%. Combined R/T and C/T or R/T alone resulted in better survival compared with C/T alone (5-year survival rates, 59%, 50%, and 15%, respectively; P = 0.01). Incidences of locoregional and systemic failure were 43% and 30%, respectively. Outcome was dismal for patients with systemic disease, with a CR rate of 43% and a 5-year survival rate of 25%. Only 2 of 21 patients had sustained remissions. The locoregional and systemic failure rates were 57% and 71%, respectively. CONCLUSIONS. Treatment outcomes were unsatisfactory for patients with locoregional and systemic sinonasal NK/T-cell or T-cell lymphoma. R/T could not control locoregional disease satisfactorily, and C/T was unable to eradicate systemic disease in many patients. High-dose therapy may be worth studying in these patients. New treatments should be investigated to increase remission rates, prevent failure, and improve survival. ? 2003 American Cancer Society. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0346724526&doi=10.1002%2fcncr.11908&partnerID=40&md5=833ab7c4e0eeb2fd088e421a62d65d97 https://scholars.lib.ntu.edu.tw/handle/123456789/537521 |
ISSN: | 0008-543X | DOI: | 10.1002/cncr.11908 | SDG/關鍵字: | antineoplastic agent; carmustine; cisplatin; cyclophosphamide; cytarabine; doxorubicin; etoposide; methotrexate; methylprednisolone; prednisolone; procarbazine; vincristine; adolescent; adult; aged; article; cancer chemotherapy; cancer radiotherapy; cancer regression; cancer survival; clinical feature; disease activity; female; human; major clinical study; male; natural killer cell; priority journal; survival rate; T cell lymphoma; treatment outcome; Adolescent; Adult; Aged; Humans; Killer Cells, Natural; Lymphoma, T-Cell; Male; Middle Aged; Nose Neoplasms; Paranasal Sinus Neoplasms; Retrospective Studies; Stem Cell Transplantation; Treatment Failure; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。